[1]易震宁,林明华.美托洛尔缓释片联合替罗非班对老年AMI患者PCI术后心血管不良事件的影响[J].医学信息,2024,37(22):54-57.[doi:10.3969/j.issn.1006-1959.2024.22.013]
　YI Zhenning,LIN Minghua.Effect of Metoprolol Succinate Sustained-release Tablets Combined with Tirofiban on Cardiovascular Adverse Events in Elderly Patients with AMI After PCI[J].Journal of Medical Information,2024,37(22):54-57.[doi:10.3969/j.issn.1006-1959.2024.22.013]
点击复制

美托洛尔缓释片联合替罗非班对老年AMI患者PCI术后心血管不良事件的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年22期
页码:
54-57
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Effect of Metoprolol Succinate Sustained-release Tablets Combined with Tirofiban on Cardiovascular Adverse Events in Elderly Patients with AMI After PCI
文章编号:
1006-1959（2024）22-0054-04
作者:
易震宁; 林明华
于都县人民医院介入科，江西 于都 342300
Author(s):
YI Zhenning; LIN Minghua
Interventional Department of Yudu County People’s Hospital,Yudu 342300,Jiangxi,China
关键词:
美托洛尔缓释片; 替罗非班; 老年AMI; PCI术; 心血管不良事件
Keywords:
Metoprolol succinate sustained-release tablets; Tirofiban; Elderly AMI; PCI technique; Cardiovascular adverse events
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2024.22.013
摘要:
目的 观察美托洛尔缓释片+替罗非班对老年急性心肌梗死（AMI）患者经皮冠状动脉介入（PCI）术后心血管不良事件的影响。方法 选取2022年10月-2023年10月在我院诊治的78例AMI行PCI术治疗的老年患者为研究对象，采用随机数字表法分为对照组（n=39）和观察组（n=39）。对照组采用阿司匹林肠溶片+阿托伐他汀钙片治疗，观察组在对照组基础上给予美托洛尔缓释片+替罗非班治疗。比两组心功能指标[左室射血分数（LVEF）、左心室收缩末期容积（LVESV）、左心室舒张末期容积（LVEDV）]、心血管不良事件（心律失常、心肌再次梗死、严重心力衰竭、死亡）发生率、生活质量水平（SF-36）、血小板计数、血小板聚集率及不良反应发生率。结果 两组LVEF高于治疗前，LVESV、LVEDV低于治疗前，且观察组LVEF高于对照组，LVESV、LVEDV低于对照组（P＜0.05）；观察组心血管不良事件发生率（10.26%）低于对照组（20.51%）（P＜0.05）；两组SF-36评分均高于治疗前，且观察组高于对照组（P＜0.05）；两组血小板计数、血小板聚集率均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 美托洛尔缓释片+替罗非班对老年AMI患者PCI术后心血管不良事件具有积极的影响，可预防并发症，减小血小板计数和聚集，改善心功能指标，提高患者术后生活质量水平，且无显著不良反应，值得临床应用。
Abstract:
Objective To observe the effect of metoprolol succinate sustained-release tablets+tirofiban on cardiovascular adverse events in elderly patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).Methods A total of 78 elderly patients with AMI who underwent PCI in our hospital from October 2022 to October 2023 were selected as the research objects. They were divided into control group (n=39) and observation group (n=39) by random number table method. The control group was treated with aspirin enteric-coated tablets +atorvastatin calcium tablets, and the observation group was treated with metoprolol succinate sustained-release tablets+tirofiban on the basis of the control group. The cardiac function indexes [left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV)], incidence of cardiovascular adverse events (arrhythmia, myocardial re-infarction, severe heart failure, death), quality of life level (SF-36), platelet count, platelet aggregation rate and incidence of adverse reactions were compared between the two groups.Results LVEF in the two groups was higher than that before treatment, LVESV and LVEDV were lower than those before treatment, and LVEF in the observation group was higher than that in the control group, LVESV and LVEDV were lower than those in the control group (P<0.05). The incidence of cardiovascular adverse events in the observation group (10.26%) was lower than that in the control group (20.51%) (P<0.05). The SF-36 score of the two groups was higher than that before treatment, and that of the observation group was higher than that of the control group (P<0.05). The platelet count and platelet aggregation rate of the two groups were lower than those before treatment, and those of the observation group were lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Metoprolol succinate sustained-release tablets+tirofiban has a positive effect on cardiovascular adverse events after PCI in elderly patients with AMI. It can prevent complications, reduce platelet count and aggregation, improve cardiac function indicators, and improve postoperative quality of life of patients without significant adverse reactions, which is worthy of clinical application.

参考文献/References:

[1]郝清卿,王立立,安少波,等.重组尿激酶原联合替罗非班在急性心肌梗死介入治疗中的作用[J].中国临床药理学杂志,2017,33(21):2098-2100.[2]吴雷,耿国英,赵明虎.美托洛尔与比索洛尔治疗舒张性心力衰竭的疗效和安全性比较[J].中国药房,2016,27(18):2488-2490.[3]洪涛.欧洲心脏病学会2017版急性ST段抬高型心肌梗死诊断和治疗指南更新之我见[J].中国介入心脏病学杂志,2017,25(9):483-485.[4]张健发,于雁飞,黄定.替格瑞洛联合替罗非班在ST段抬高型心肌梗死糖尿病患者急诊 PCI 术中的应用和安全性[J].中国老年学杂志,2017,37(5):1098-1101.[5]毛霄鹏,严语.替格瑞洛与氯吡格雷对经皮冠状动脉介入术治疗的ST段抬高型心肌梗死患者的临床疗效[J].中国临床药理学杂志,2016,32(9):786-788.[6]刘杰,宋书凯.早期应用不同剂量替罗非班在急性ST段抬高型心肌梗死患者中的临床观察[J].天津医科大学学报,2017,23(1):59-62.[7]赵纯华.依替巴肽与替罗非班在急性ST段抬高型心肌梗死病人PCI治疗中的疗效及安全性对比研究[J].中西医结合心脑血管病杂志,2017,15(19):2434-2437.[8]Lattuca B,Kerneis M,Zeitouni M,et al.Elderly patients with ST-segment elevation myocardial infarction: a patient-centered approach[J].Drugs Aging,2019,36(6):531-539.[9]段小春,曾玉杰,刘梅颜,等.替罗非班对急性ST段抬高型心肌梗死患者血小板抑制率的影响及安全性评价[J].中国循证心血管医学杂志,2019,11(6):739-741.[10]周召锋,施亚明,王斌,等.替格瑞洛联合冠状动脉内注射替罗非班对 STEMI 急诊PCI 后心肌灌注和预后的影响[J].江苏医药,2017,43(11):790-793.[11]皮淑芳,刘迎午,李彤,等.尼可地尔对急性ST段抬高型心肌梗死患者直接经皮冠状动脉介入术后临床效果的影响[J].天津医药,2018,46(7):724-728.[12]龚肖丽,吕新湖,米杰,等.替罗非班对急性心肌梗死患者 PCI术后血小板活化功能、TIMI血流分级及心肌梗死面积的影响[J].河北医药,2016,38(9):1330-1332.[13]Kawada T.High-sensitivity cardiac troponin T in patients with ST-segment elevation myocardial infarction[J].J Cardiol,2019,73(4):333.[14]齐琪,牛竞辉,陈涛,等.尼可地尔联合替罗非班对急性 ST 段抬高型心肌梗死患者 PPCI 无复流的疗效观察[J].河北医科大学学报,2017,38(7):750-755.[15]廖开历,蓝璧高.尼可地尔联合替罗非班对老年ST段抬高型心肌梗死患者经皮冠状动脉介入术术后即刻心肌血流灌注和预后的影响[J].广西医学,2019,41(23):3005-3008.[16]张艳霞,张一平.替罗非班联合美托洛尔治疗急性心肌梗死的疗效观察[J].现代药物与临床,2021,36(2):331-334. [17]程军,魏婕,方洁,等.比伐卢定对行PCI治疗高危ACS患者的抗凝效果及对犯罪血管的影响分析[J].临床和实验医学杂志,2020,19(18):1952-1955.[18]齐明旭,贺丽.替罗非班在老年糖尿病合并急性心肌梗死PCI治疗中的价值与安全性研究[J].吉林医学,2020,41(1):149-150.[19]王楚林,吴强,徐名伟,等.PCI术联合替罗非班对AMI患者TDR的影响及其预后的危险因素[J].心血管康复医学杂志,2021,30(1):51-56.[20]王颖,姜世平.早期应用盐酸替罗非班在ST段抬高型急性心肌梗死患者急诊PCI治疗中的临床效果分析[J].中外医学研究,2016,14(24):26-27,28.

相似文献/References:

[1]雷 锐,李 志.冠状动脉介入及替罗非班治疗老年急性心肌梗死并 心源性休克的疗效分析[J].医学信息,2018,31(14):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
　LEI Rui,LI Zhi.Effect of Coronary Intervention and Tirofiban on Elderly Patients with Acute Myocardial Infarction and Cardiogenic Shock[J].Journal of Medical Information,2018,31(22):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
[2]王 楠.替罗非班对急性缺血性脑卒中患者新发脑微出血的影响[J].医学信息,2021,34(14):114.[doi:10.3969/j.issn.1006-1959.2021.14.030]
　WANG Nan.The Effect of Tirofiban on New Cerebral Microhemorrhage in Patients with Acute Ischemic Stroke[J].Journal of Medical Information,2021,34(22):114.[doi:10.3969/j.issn.1006-1959.2021.14.030]
[3]王 英,李彤彤,王 燕,等.替罗非班对急性缺血性卒中大鼠PI3K/Akt/eNOS通路及神经损伤的影响[J].医学信息,2022,35(07):66.[doi:10.3969/j.issn.1006-1959.2022.07.016]
　WANG Ying,LI Tong-tong,WANG Yan,et al.Effects of Tirofiban on PI3K/Akt/eNOS Pathway and Nerve Injury in Rats with Acute Ischemic Stroke[J].Journal of Medical Information,2022,35(22):66.[doi:10.3969/j.issn.1006-1959.2022.07.016]
[4]熊鹏锋.沙库巴曲缬沙坦联合美托洛尔对青年扩张型心肌病患者心功能及预后的影响[J].医学信息,2022,35(20):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
　XIONG Peng-feng.Effect of Sacubitril Valsartan Combined with Metoprolol on Cardiac Function and Prognosis in Young Patients with Dilated Cardiomyopathy[J].Journal of Medical Information,2022,35(22):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
[5]雷 锐,李 志.PCI术前应用替罗非班对急性心肌梗死患者PCI治疗效果的影响[J].医学信息,2022,35(21):119.[doi:10.3969/j.issn.1006-1959.2022.21.030]
　LEI Rui,LI Zhi.Effect of Tirofiban on PCI in Patients with Acute Myocardial Infarction Before PCI[J].Journal of Medical Information,2022,35(22):119.[doi:10.3969/j.issn.1006-1959.2022.21.030]
[6]何佳纹.美托洛尔缓释片联合冠心苏合胶囊治疗冠心病不稳定型心绞痛的效果[J].医学信息,2025,38(02):120.[doi:10.3969/j.issn.1006-1959.2025.02.022]
　HE Jiawen.Effect of Metoprolol Sustained-release Tablets Combined with Guanxin Suhe Capsules in the Treatment of Unstable Angina Pectoris of Coronary Heart Disease[J].Journal of Medical Information,2025,38(22):120.[doi:10.3969/j.issn.1006-1959.2025.02.022]

更新日期/Last Update: 1900-01-01